Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Erbitux Sales to Exceed 1 Bil. Euro Mark
August 10, 2009
- Combination Drugs Interfere with Promotion of Generics: JSHP
August 10, 2009
- No. 3 and No. 4 CSOs to Merge
August 10, 2009
- Establish Regional Networks to Promote Use of Generics: Mr Kinoshita
August 10, 2009
- BUSINESS NEWS IN BRIEF
August 10, 2009
- BUSINESS NEWS IN BRIEF
August 3, 2009
- Can You Tell a Good Story?
August 3, 2009
- Doctors' Sources of Information on ARBs Investigated by So-net M3
August 3, 2009
- Medical Expenditures Up 1.9% to ¥34.1 Tril. In FY2008
August 3, 2009
- Eisai Submits First Application for E7389 in Switzerland
August 3, 2009
- Only 40% of Consumers Have Single Regular Pharmacies: JPA
August 3, 2009
- FDA Extends NDA Review for Alogliptin and ACTOS Combination
August 3, 2009
- Isentress Should Be Used in First-Line Therapy: Dr Hanabusa
August 3, 2009
- Sitagliptin, Sibutramine Recommended for Approval
August 3, 2009
- Exceptional NHI Price Maintenance System Benefits Patients: Mr Nagano
August 3, 2009
- Generics, Drug Pricing Not Included in DPJ's Manifesto
August 3, 2009
- REGULATORY NEWS IN BRIEF
August 3, 2009
- Share of Generics Up 1.9 Points to 18.0% on a Volume Basis
August 3, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 3, 2009
- Kure City to Save Over ¥100 Mil. by Generics Use-Promotion Notification Service
August 3, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…